Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 9, 2015, Pages 399-406

  Haugnes, Hege S ^a,b   Oldenburg, Jan ^c   Bremnes, Roy M ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cardiovascular; Chemotherapy; Long term effects; Pulmonary; Radiotherapy; Testicular cancer survivors

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; TESTOSTERONE; ANTINEOPLASTIC AGENT;

AGE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSPIRED OXYGEN FRACTION; KIDNEY FUNCTION; LIFESTYLE; LUNG DISEASE; LUNG EMBOLISM; LUNG FUNCTION; LUNG FUNCTION TEST; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT PARAMETERS; REVIEW; RISK FACTOR; SMOKING; TESTIS CANCER; TESTOSTERONE BLOOD LEVEL; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; DRUG EFFECTS; LUNG; LUNG DISEASES; MALE; RADIOTHERAPY; SURVIVOR; TESTICULAR NEOPLASMS;

ANTINEOPLASTIC AGENTS; BLEOMYCIN; CARDIOVASCULAR DISEASES; CISPLATIN; HUMANS; LUNG; LUNG DISEASES; MALE; RADIOTHERAPY; SURVIVORS; TESTICULAR NEOPLASMS;

EID: 84940467273     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.11.012     Document Type: Review

References (80)

1. Larsen IK, Larønningen, S, Johannesen, T, et al. Cancer in Norway 2012-cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway. ; 2014 [accessed 07.08.14]. http://www.kreftregisteret.no.
2. Einhorn L.H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977, 87:293-298.
3. Williams S.D., Birch R., Einhorn L.H., et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987, 316:1435-1440.
4. Fossa S.D., Aass N., Harvei S., Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 2004, 90:607-612.
5. Fossa S.D., Gilbert E., Dores G.M., et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007, 99:533-544.
6. Haugnes H.S., Bosl G.J., Boer H., et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012, 30:3752-3763.
7. Aziz N.M. Cancer survivorship research: state of knowledge, challenges and opportunities. Acta Oncol 2007, 46:417-432.
8. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001, 120:617-624.
9. Comis R.L., Kuppinger M.S., Ginsberg S.J., et al. Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res 1979, 39:5076-5080.
10. Strumberg D., Brugge S., Korn M.W., et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002, 13:229-236.
11. Sleijfer S., van der Mark T.W., Schraffordt K.H., Mulder N.H. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer 1995, 71:120-123.
12. O'Sullivan J.M., Huddart R.A., Norman A.R., et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003, 14:91-96.
13. Simpson A.B., Paul J., Graham J., Kaye S.B. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998, 78:1061-1066.
14. Nuver J., Lutke Holzik M.F., Van Z.M., et al. Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genomics 2005, 15:399-405.
15. Motzer R.J., Nichols C.J., Margolin K.A., et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007, 25:247-256.
16. Culine S., Kerbrat P., Kramar A., et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007, 18:917-924.
17. de Wit R., Stoter G., Kaye S.B., et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997, 15:1837-1843.
18. de Wit R., Roberts J.T., Wilkinson P.M., et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001, 19:1629-1640.
19. de Haas E.C., Zwart N., Meijer C., et al. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol 2008, 26:1817-1823.
20. Gupta R., Ettinger N.A. Beyond conventional therapy: role of pulse steroids in bleomycin induced lung injury. Respir Care 2014, 59:e9-e12.
21. Carnevale-Schianca F., Gallo S., Rota-Scalabrini D., et al. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin[U+05F3]s lymphoma: hope for severe chemotherapy-induced toxicity?. J Clin Oncol 2011, 29:e691-e693.
22. Lucraft H.H., Wilkinson P.M., Stretton T.B., Read G. Role of pulmonary function tests in the prevention of bleomycin pulmonary toxicity during chemotherapy for metastatic testicular teratoma. Eur J Cancer Clin Oncol 1982, 18:133-139.
23. Osanto S., Bukman A., Van H.F., et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992, 10:574-579.
24. Hansen S.W., Groth S., Sorensen P.G., et al. Enhanced pulmonary toxicity in smokers with germ-cell cancer treated with cis-platinum, vinblastine and bleomycin: a long-term follow-up. Eur J Cancer Clin Oncol 1989, 25:733-736.
25. Van Barneveld P.W., Sleijfer D.T., van der Mark T.W., et al. Natural course of bleomycin-induced pneumonitis. A follow-up study. Am Rev Respir Dis 1987, 135:48-51.
26. Feldman D.R., Bosl G.J., Sheinfeld J., Motzer R.J. Medical treatment of advanced testicular cancer. J Am Med Assoc 2008, 299:672-684.
27. Goldiner P.L., Carlon G.C., Cvitkovic E., et al. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1978, 1:1664-1667.
28. Douglas M.J., Coppin C.M. Bleomycin and subsequent anaesthesia: a retrospective study at Vancouver General Hospital. Can Anaesth Soc J 1980, 27:449-452.
29. Donat S.M., Levy D.A. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?. J Urol 1998, 160:1347-1352.
30. de Wit R., Sleijfer S., Kaye S.B., et al. Bleomycin and scuba diving: where is the harm?. Lancet Oncol 2007, 8:954-955.
31. Haugnes H.S., Aass N., Fossa S.D., et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009, 27:2779-2786.
32. Thomsen F.B., Bandak M., Thomsen M.F., et al. Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older. Cancer 2014, 120:43-51.
33. Sleijfer S., van der Mark T.W., Schraffordt Koops H., Mulder N.H. Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin. Eur J Cancer 1996, 32A:550-552.
34. Lower E.E., Strohofer S., Baughman R.P. Bleomycin causes alveolar macrophages from cigarette smokers to release hydrogen peroxide. Am J Med Sci 1988, 295:193-197.
35. Boyer M., Raghavan D., Harris P.J., et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990, 8:21-26.
36. Bastion Y., Reyes F., Bosly A., et al. Possible toxicity with the association of G-CSF and bleomycin. Lancet 1994, 343:1221-1222.
37. Saxman S.B., Nichols C.R., Einhorn L.H. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997, 111:657-660.
38. Schunemann H.J., Dorn J., Grant B.J.B., et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000, 118:656-664.
39. Mannino D.M., Buist A.S., Petty T.L., et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003, 58:388-393.
40. Smith S.C., Collins A., Ferrari R., et al. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Eur Heart J 2012, 33:2910-2916.
41. Yusuf S., Hawken S., Ôunpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
42. Timp J.F., Braekkan S.K., Versteeg H.H., Cannegieter S.C. Epidemiology of cancer-associated venous thrombosis. Blood 2013, 122:1712-1723.
43. Weijl N.I., Rutten M.F., Zwinderman A.H., et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000, 18:2169-2178.
44. Moore R.A., Adel N., Riedel E., et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011, 29:3466-3473.
45. Khorana A.A., Kuderer N.M., Culakova E., et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008, 111:4902-4907.
46. Doll D.C., List A.F., Greco F.A., et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986, 105:48-51.
47. Dieckmann K.P., Gerl A., Witt J., et al. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 2010, 21:1607-1611.
48. Meinardi M.T., Gietema J.A., van der Graaf W.T., et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000, 18:1725-1732.
49. Zagars G.K., Ballo M.T., Lee A.K., Strom S.S. Mortality after cure of testicular seminoma. J Clin Oncol 2004, 22:640-647.
50. van den Belt-Dusebout A., Nuver J., de Wit R., et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006, 24:467-475.
51. Haugnes H.S., Wethal T., Aass N., et al. Cardiovascular risk factors and morbidity in testicular cancer survivors: A 20 year follow-up study. J Clin Oncol 2010, 28:4649-4657.
52. Huddart R.A., Norman A., Shahidi M., et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003, 21:1513-1523.
53. Lauritzen J, Mortensen MS, Gundgaard MG, et al. Risk of cardiovascular disease, diabetes and death in germ-cell survivors in a large cohort. ECCO 17; 2013. [Abstract].
54. Sagstuen H., Aass N., Fossa S.D., et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005, 23:4980-4990.
55. Willemse P.M., Burggraaf J., Hamdy N.A., et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer 2013, 109:60-67.
56. Haugnes H.S., Aass N., Fossa S.D., et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007, 18:241-248.
57. Alberti K.G., Zimmet P., Shaw J., et al. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
58. Nuver J., Smit A.J., Wolffenbuttel B.H., et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005, 23:3718-3725.
59. Altena R., de Haas E.C., Nuver J., et al. Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer 2009, 100:1861-1866.
60. van Schinkel L.D., Willemse P.M., van der Meer R.W., et al. Chemotherapy for testicular cancer induces acute alterations in diastolic heart function. Br J Cancer 2013, 109:891-896.
61. Altena R., Hummel Y.M., Nuver J., et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 2011, 22:2286-2293.
62. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.
63. Nuver J., Smit A.J., van der Meer J., et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005, 23:9130-9137.
64. Nuver J., de Haas E.C., Van Z.M., et al. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010, 23:247-253.
65. Nuver J., Smit A.J., Sleijfer D.T., et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004, 40:701-706.
66. de Haas E.C., Zwart N., Meijer C., et al. Association of PAI-1 gene polymorphism with survival and chemotherapy-related vascular toxicity in testicular cancer. Cancer 2010, 116:5628-5636.
67. Vaughn D.J., Palmer S.C., Carver J.R., et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008, 112:1949-1953.
68. Brouwers E., Huitema A., Beijnen J., Schellens J. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 2008, 8:1-10.
69. Sprauten M., Darrah T.H., Peterson D.R., et al. Impact of long-term platinum concentrations on neuro- and ototoxicity in cisplatin-treated testicular cancer survivors. J Clin Oncol 2012, 30:300-307.
70. Travis L.B., Beard C., Allan J.M., et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010, 102:1114-1130.
71. Haring R., Volzke H., Steveling A., et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010, 31:1494-1501.
72. Laaksonen D.E., Niskanen L., Punnonen K., et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004, 27:1036-1041.
73. Svartberg J., Schirmer H., Medbo A., et al. Reduced pulmonary function is associated with lower levels of endogenous total and free testosterone. The Tromso study. Eur J Epidemiol 2007, 22:107-112.
74. Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008, 93:68-75.
75. Jones T.H., Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009, 207:318-327.
76. Jones T.H., Arver S., Behre H.M., et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011, 34:828-837.
77. Xu L., Freeman G., Cowling B., Schooling C. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013, 11:108.
78. Sandvik L.E.G., Thaulow E. Long term effects of smoking on physical fitness and lung function: a longitudinal study of 1393 middle aged Norwegian men for seven years. Br Med J 1995, 311:715-718.
79. Demark-Wahnefried W., Jones L.W. Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am 2008, 22:319-342. [viii].
80. Demark-Wahnefried W., Aziz N.M., Rowland J.H., Pinto B.M. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005, 23:5814-5830.